◈ Nootpedia
Compact view
Research pass: thorough AAS · Oil injectable SKIP-FOR-NOW MEDIUM

Boldenone Undecylenate

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

For Dylan-archetype (20yo, peak natural T, brain-priority, MMA athlete on 185-190 lb / 6'0-6'1 frame, no aesthetic / mass goals stated as priorities) — boldenone is a B-tier body-comp tool from a class that's a SKIP-AT-20 across the board. Same family logic as testosterone-enanthate, methenolone, trenbolone: HPG-axis suppression at 20 risks permanent shutdown of an HPG axis still maturing; lipid (HDL crash + LDL/oxLDL rise), polycythemia (boldenone is among the most RBC-elevating AAS — clinically relevant hematocrit elevation is documented), and BP elevation are core signals; gray-market sourcing means QC variance + counterfeit risk; veterinary-grade injectables carry contamination concerns. MEDIUM (not HIGH) confidence because boldenone is genuinely milder than trenbolone or testosterone on the side-effect profile (less DHT-pathway, less aromatization, no neurosides) — if Dylan ever decides to run AAS post-30 with bloodwork backing, EQ is one of the more defensible Tier-2 picks. But "milder than tren" is not "good idea at 20." Aesthetic / mass goals are explicitly downstream in the priority stack, brain wins over body, and the appetite stimulation that's part of the EQ value proposition is irrelevant for a 185-190 lb athlete who's already hitting protein. Would change verdict only if Dylan reaches 28-30+, completes a final-state HPG / fertility checkpoint, has a documented competitive aesthetic goal, AND has measured baseline + monitoring plan.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload, athletic (Dylan-archetype)
    SKIP-AT-

    Same-family AAS logic. HPG-axis suppression at 20 risks long-term shutdown of a still-maturing axis; lipid + polycythemia + BP signals are real; gray-market sourcing has QC + contamination risk; aesthetic / mass goals are explicitly downstream of brain + MMA in Dylan's priority stack. No documented cognitive benefit; possible cognitive cost from polycythemia-driven viscosity. WADA-banned (irrelevant for untested status). Long urine detection window (5-12 months) precludes any later sanctioned competition for ~1 year post-cycle.

  • 30-50, executive maintenance, lifestyle-optimized, low TRT borderline
    NOT-INDICATED

    If clinical hypogonadism is documented, [testosterone-enanthate](testosterone-enanthate.md) Rx via TRT clinic is the indicated tool, not boldenone. Boldenone has no clinical indication that testosterone doesn't already cover.

  • 30-50, recreational physique optimization, post-baseline-monitoring
    OPTIONAL-ADD

    as Tier-2 cycle component if and only if (a) on TRT base, (b) full baseline + on-cycle monitoring (lipids, hematocrit, BP, E2), (c) explicit mass / aesthetic goal, (d) prior AAS experience. EQ is one of the more defensible Tier-2 picks within AAS — milder than tren, mostly non-DHT, non-hepatotoxic. Still carries class-wide cardiovascular and HPG-axis risks.

  • 50+, recovery / quality-of-life optimization
    NOT-INDICATED

    Polycythemia risk grows with age; cardiovascular risk grows with age. TRT (if indicated) at low-normal-restoration doses is a different conversation; recreational AAS use at 50+ is not.

  • Anxiety-prone
    AVOID

    Persistent community report of EQ-induced anxiety; mechanism uncertain but signal exists.

  • High athletic load, tested status (any combat sport, endurance, strength competing in WADA-tested events)
    SKIP

    WADA S1.1a banned, 5-12 month urine detection window.

  • Sleep-disordered
    AVOID

    if sleep apnea / nocturnal-hypoxia component — RBC mass + BP + neck soft-tissue effects can worsen sleep apnea.

  • Recovery-focused (post-injury, post-illness)
    NOT-INDICATED

    [BPC-157](bpc-157.md), [TB-500](tb-500.md), [GHK-Cu](ghk-cu.md) are mechanism-aligned for tissue repair without HPG / cardiovascular cost.

  • Strength/anabolic-focused, post-30, fully baselined
    OPTIONAL-ADD

    as Tier-2 / Tier-3 cycle component. Lean-quality reputation is real; pair with TRT base + AI + monitoring.

  • Veterinary equine
    PRIMARY-PICK

    for the equine indication (the only FDA-approved use case). Not relevant to human protocol design.

▸ Subjective experience (deep)
  • Onset: Slow. Even with frontloading, most users describe nothing meaningful until week 4-6. Full effect at week 8-12.
  • Peak effect: Lean mass accrual (slow), increased vascularity, mild-to-moderate appetite stimulation, libido elevation, mild RBC-driven endurance improvement.
  • Mood: Neutral-to-positive in most users; a meaningful minority report increased anxiety (ill-characterized — possibly metabolite-related, possibly individual variation, possibly polycythemia-driven).
  • Sleep: Mostly neutral; some users report improved sleep depth (libido / well-being effect), others report mild sleep disruption (likely RBC / BP / arousal effects at higher doses).
  • Cognitive: Mostly neutral. Some users report mild "cognitive fog" at higher doses — possibly polycythemia-related (increased blood viscosity reducing cerebral perfusion). No mechanism-aligned cognitive benefit.
  • Discontinuation: Long taper-out — undecylenate ester continues releasing for 4-6+ weeks after last injection. HPG axis stays suppressed for the full taper plus recovery period. Post-cycle therapy (PCT) is essential and must be timed to the ester clearance, not the last injection.
▸ Tolerance + cycling deep dive
  • Tolerance: AAS-class shows mild AR-density downregulation with sustained use; clinical tolerance is real but modest. Not the rate-limiting factor for cycle design.
  • Recommended cycle length: 12-16 weeks for the long undecylenate ester (shorter cycles waste the ester's slow onset). Many bodybuilders run 16-20 week cycles with EQ.
  • Reset protocol: PCT (see Dosing). Time off equal to time on (TOE = TON) is a common community heuristic; in practice, full HPG / lipid / cardiovascular recovery often takes longer than time-on.
  • Cumulative cycle damage: Lipid changes, cardiac structural changes, and HPG dysfunction integrate over years of cycling. The "blast and cruise" pattern (cycles followed by TRT-doses indefinitely) is increasingly common in long-term AAS users and represents permanent commitment to exogenous T.
▸ Stacking deep dive

Synergistic with

  • (For appropriate populations only — i.e., NOT Dylan-archetype at 20) testosterone-enanthate: Standard "TRT base" companion to any AAS cycle. Provides the testosterone the user no longer makes endogenously.
  • methenolone (Primobolan): "Quality lean" stacking partner — both mild AAS, both non-alkylated, both relatively HPG-friendly within the class. Common Tier-2 cycle composition.
  • Aromatase inhibitor (anastrozole, letrozole): Standard estrogen-management adjunct; titrated against E2 sensitive-assay levels.
  • HCG (250-500 IU 2× weekly during cycle): Maintains testicular volume / responsiveness; often used to ease PCT. Not a substitute for PCT.

Avoid stacking with

  • trenbolone: Combined polycythemia, BP elevation, lipid disturbance, and cardiac stress profile. Tren+EQ stacks are common in advanced bodybuilding but represent a substantial step-up in cardiovascular risk.
  • Other strong erythropoietic AAS: Stacking EQ with anything else that strongly elevates RBC mass (e.g., high-dose testosterone, nandrolone) compounds polycythemia risk.
  • 17α-alkylated orals (dianabol, anavar, winstrol): Hepatotoxicity stacking; cumulative liver burden during multi-month cycles.
  • NSAIDs (chronic): BP / kidney load stacking with the BP-elevating effect of EQ.

Neutral / safe co-administration

  • Most CNS nootropics (modafinil, racetams, citicoline, magnesium) — no direct interaction
  • Vitamin D, omega-3, basic micronutrient stack — no interaction
  • Most antibiotics, antihistamines — no interaction at typical doses
▸ Drug interactions deep dive
  • Warfarin / DOACs: Theoretical interaction via lipid panel / hepatic CYP changes; AAS users on anticoagulation need monitoring.
  • Insulin / oral antidiabetics: AAS class generally improves insulin sensitivity at moderate doses but can worsen at high doses; monitor.
  • Antihypertensives: Often need uptitration on cycle.
  • CYP induction/inhibition: Boldenone is metabolized via 17β-HSD and downstream pathways; some hepatic CYP3A4 induction at high doses but not clinically dominant.
  • Levothyroxine / thyroid hormones: AAS may alter SHBG / free hormone fractions; recheck thyroid panel on cycle if symptomatic.
  • Estrogen-containing products: Counter-pharmacodynamic; not relevant for typical male users.
▸ Pharmacogenomics
  • AR (androgen receptor) CAG repeat length: Shorter CAG repeats → more sensitive AR → stronger response per mg AAS, including stronger DHT-pathway side effects. Trackable on 23andMe via manual analysis.
  • CYP19A1 (aromatase) variants: Influence aromatization rate; some users are "high aromatizers" requiring more aggressive AI use.
  • SRD5A2 (5α-reductase type 2) variants: Affect DHT-pathway side effect profile.
  • HFE / iron-metabolism variants: Compound polycythemia risk if iron-loading variants present.
  • APOE / lipid-metabolism variants: APOE ε4 carriers may show worse lipid response to AAS.
  • Practical takeaway for Dylan: No actionable pharmacogenomics for prescribing decisions because the prescribing decision is "don't." 23andMe results (June 2026) will inform any future AAS conversation post-30 if priorities shift.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (human) None — no human FDA approval N/A N/A Boldenone has never been approved for human use in any major regulatory jurisdiction. Compounding pharmacy access exists in limited contexts but is gray-zone.
US Rx (veterinary) Equipoise (Fort Dodge / Zoetis), licensed veterinarian, equine indication $150-300 / 50 mL × 50 mg/mL bottle High (genuine product) Diversion of veterinary product into human use is illegal and increasingly enforced. Veterinary preservatives / vehicles are not formulated for human SC/IM use; injection-site reactions, sterility concerns, and label dose mismatch are documented.
Gray-market underground lab (UGL) Various — quality varies wildly $40-100 / 10 mL × 200-300 mg/mL vial Variable Most common path for human use. Reputable UGLs publish HPLC + sterility testing (Janoshik is the standard independent lab); many do not. Counterfeit / underdosed / contaminated product is documented.
Compounding pharmacy (US) Limited 503A access $200-400 / 10 mL Variable Tightening regulation since 2020s; off-label boldenone compounding is increasingly rare.
International pharmaceutical-grade (Mexico, India, China, Eastern Europe) Various Variable Variable Crossing border with these is a controlled-substance felony under US federal law.

Quality concerns with gray-market:

  • Boldenone undecylenate is among the more commonly underdosed AAS in UGL testing (the long-chain ester eats vial mass — manufacturers sometimes cheat the boldenone:ester ratio).
  • Bacterial contamination of injectable oil from inadequately sterilized UGL operations has produced abscesses, sepsis, and local-tissue infections.
  • Carrier oil (cottonseed, sesame, MCT, ethyl oleate) contamination produces injection-site reactions, post-injection pain ("PIP"), and in some cases sterile abscesses.
  • Counterfeit Equipoise (vials labeled as Fort Dodge but synthesized by UGL) is common in the wild.

Note for Dylan: Sourcing is solvable (UGL path is well-established at 20yo athletic-community access). The verdict isn't "can't get it" — it's "shouldn't take it at 20." Veterinary-grade injection in particular adds non-trivial sterility / contamination risk to an already-questionable risk-benefit calculation.

▸ Biomarkers to track (deep)
  • Baseline (before cycling, ideally 2-4 weeks of fasted-AM panels for stability):
    • Total testosterone, free testosterone, SHBG (LC-MS preferred)
    • Estradiol (sensitive assay, LC-MS or ECLIA)
    • LH, FSH
    • Hematocrit, hemoglobin, RBC count, MCV, ferritin
    • Lipid panel: LDL-C, HDL-C, ApoB, oxLDL (if available), Lp(a) (one-time genetic-set baseline)
    • ALT, AST, GGT, alkaline phosphatase
    • Comprehensive metabolic panel (creatinine, eGFR, electrolytes)
    • Blood pressure (24-hr ambulatory ideal; multiple manual readings minimum)
    • Resting heart rate, ECG baseline
    • PSA (>30yo)
    • Sperm analysis (if fertility-relevant)
    • Echocardiogram (>30yo or with prior cycles or family CV history)
  • During use (every 4-6 weeks on cycle):
    • Hematocrit, hemoglobin (every 4 weeks; threshold for action: HCT >54%)
    • Lipid panel (every 8-12 weeks; expect HDL crash, LDL/ApoB rise)
    • Total / free T, E2 sensitive (every 6-8 weeks for AI titration)
    • LH, FSH (1× mid-cycle to confirm suppression — clinical interest only)
    • BP, resting HR (weekly self-tracking; clinical re-check every 4 weeks)
    • ALT, AST (every 6-8 weeks)
    • Symptom log: anxiety, sleep changes, libido, joint pain, gyno surveillance
  • Post-cycle (PCT through recovery):
    • Total / free T, LH, FSH every 4-6 weeks until recovered (12-24 weeks typical)
    • E2 sensitive (post-AI clearance can produce E2 rebound)
    • Lipid panel re-baseline at 12 weeks post
    • Hematocrit re-baseline at 8 weeks post
    • Sperm analysis at 6 months post if fertility-relevant
    • BP, resting HR re-baseline at 4-8 weeks post
▸ Controversies / open debates Live debate
  1. The "milder than testosterone" claim. The 100:50 anabolic:androgenic rating from rat assays is still cited as if it cleanly translates to humans. In practice, individual variation (AR sensitivity, aromatase activity, 5α-reductase activity) often dominates. The mildness is real on average for DHT-pathway side effects; less reliable for HPG suppression and cardiovascular markers.
  2. The anxiety side effect. Persistent community report; never well-characterized in literature. Possibilities: 1-dehydroestradiol metabolite acting differently from estradiol, blood-viscosity effects on cerebral perfusion, individual variation, recall bias. Real users report it; mechanism research has not pursued it.
  3. Counterfeit / underdosing prevalence. Independent UGL testing (Janoshik, Anabolic Lab, others) consistently finds boldenone undecylenate among the more frequently underdosed AAS — possibly because the long-chain ester takes up significant vial mass, tempting manufacturers to cheat the boldenone:ester ratio. Real-world potency is more variable than vial labels suggest.
  4. Veterinary vs. human grade. Whether veterinary product (Equipoise) is "safer" or "more dangerous" than UGL human-grade is a long-running community debate. Veterinary product is genuine FDA-approved manufacturing for the labeled indication; human use is off-label and the formulation isn't designed for human SC/IM. UGL human-grade is variable. No clean answer.
  5. Long-term cardiovascular damage and reversibility. AAS-induced cardiomyopathy is documented; partial reversibility on discontinuation is documented; full reversibility is not consistently shown. Boldenone-specific contribution within cycles is impossible to isolate.
  6. The case for EQ as a "first cycle" choice. Some community resources position EQ as a reasonable first cycle (mild, non-hepatotoxic, lean gains). Others argue testosterone-only is the better first cycle (single-variable assessment, well-characterized, readily Rx-available via TRT clinic). The latter view is stronger in evidence-based bodybuilding circles in 2024-2026.
  7. The fertility recovery question. Long-ester AAS (boldenone, testosterone enanthate, nandrolone) consistently produce longer HPG recovery than short-ester or oral AAS. How long is genuinely individual; some users recover in 12 weeks, others in 18 months, a small fraction never recover full pre-cycle T levels. Age at first cycle is a meaningful predictor — younger users have better recovery on average, but younger users also have more years of fertility ahead of them.
  8. For Dylan specifically: Verdict is robust. Only physiologic / priority-state change (post-30, competitive aesthetic goal, completed fertility checkpoint, full monitoring framework) would re-open the question.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-AT-20 (MEDIUM confidence) for Dylan. Rationale: same-family AAS logic — HPG suppression at 20 risks permanent shutdown of a still-maturing axis; lipid + polycythemia + BP signals are real; brain/MMA priorities sit above aesthetic/mass goals; gray-market sourcing has QC and contamination risk. MEDIUM (not HIGH) confidence because boldenone is genuinely milder than trenbolone or testosterone on aromatization and DHT pathways — if Dylan ever pivots post-30 to AAS use with full baseline + monitoring, EQ is one of the more defensible Tier-2 picks. OPTIONAL-ADD for 30-50 fully-baselined recreational physique optimization with TRT base. NOT-INDICATED for clinical TRT, recovery, or cognitive optimization. PRIMARY-PICK for veterinary equine indication only. File entry exists for wiki completeness; would change to OPTIONAL-ADD for Dylan if at 28-30+ he develops competitive aesthetic / mass goals AND has completed fertility checkpoint AND has documented baseline + monitoring framework.
▸ Open questions / gaps Open
  1. No A-tier human RCTs. True for nearly all AAS; not boldenone-specific. Limits any quantitative risk estimate.
  2. Long-term cardiovascular reversibility on discontinuation. Echocardiographic findings often persist; full population-scale longitudinal data are lacking.
  3. The anxiety side effect mechanism. Real signal in user reports; no mechanistic research.
  4. Dose-response on polycythemia risk in young athletes. EQ is one of the most polycythemia-elevating AAS; the dose at which combat-sport cardiovascular load becomes unsafe is undercharacterized.
  5. Cognitive effects (positive or negative) on cycle. Not studied. Polycythemia-driven cerebral perfusion changes are theoretically real; no neurocognitive testing in AAS users has tracked this.
  6. Boldenone metabolite (1-dehydroestradiol) pharmacology. Less characterized than estradiol's; relevance to anxiety / mood reports unclear.
  7. For Dylan specifically: Verdict is robust. The open question is timing of revisit (28? 30? 32?) and trigger conditions (competitive aesthetic goal? Specific physique target? Bloodwork-confirmed natural T decline?).
▸ Sources (full, with our context)
Back to compact view